FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

NCT01647945 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Placebo
DRUG: FK506 level < 2 ng/ml
DRUG: FK506 level 2-3 ng/ml
DRUG: FK506 level 3-5 ng/ml

Sponsor

Edda Spiekerkoetter

Collaborators

[object Object]